Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athira Pharma Inc ATHA

Healthcare
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate... see more

Recent & Breaking News (NDAQ:ATHA)

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer's Disease at CTAD Conference

GlobeNewswire November 10, 2021

Athira Pharma to Present at Upcoming Investor Conferences

GlobeNewswire November 8, 2021

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

GlobeNewswire October 29, 2021

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer's Disease

GlobeNewswire October 22, 2021

Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer

GlobeNewswire October 21, 2021

Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Conference

GlobeNewswire September 29, 2021

Athira Shareholder Notice

Newsfile August 29, 2021

Athira Shareholder Alert

Newsfile August 27, 2021

Athira Deadline Alert

Newsfile August 25, 2021

CLASS ACTION UPDATE for ATHA, OTLY and AHCO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Accesswire August 24, 2021

Last Day for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Grossman, LLC

Business Wire August 24, 2021

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile August 24, 2021

ATHA DEADLINE TODAY: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firm's Attorneys Now, Lead Plaintiff Deadline Today

Newsfile August 24, 2021

ATHIRA PHARMA 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA

PR Newswire August 23, 2021

Athira Deadline Alert

Newsfile August 23, 2021

Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors - ATHA

Business Wire August 23, 2021

CLASS ACTION UPDATE for ATHA, CRMD and VIEW: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Accesswire August 23, 2021

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile August 23, 2021

LAWSUITS FILED AGAINST ATHA, PLL and ATVI - Jakubowitz Law Pursues Shareholders Claims

Accesswire August 23, 2021

Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer's Disease Summit

GlobeNewswire August 23, 2021